サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551799

非アルコール性脂肪性肝疾患治療薬の世界市場

Non-Alcoholic Fatty Liver Disease Therapeutics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
非アルコール性脂肪性肝疾患治療薬の世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

非アルコール性脂肪性肝疾患治療薬の世界市場は2030年までに97億米ドルに達する

2023年に37億米ドルと推定される非アルコール性脂肪性肝疾患治療薬の世界市場は、分析期間2023-2030年にCAGR 14.6%で成長し、2030年には97億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口ルートは、CAGR 15.0%を記録し、分析期間終了時には62億米ドルに達すると予測されます。非経口ルートセグメントの成長率は、分析期間のCAGRで13.9％と推定されます。

米国市場は10億米ドルと推定、中国はCAGR19.5％で成長予測

米国の非アルコール性脂肪性肝疾患治療薬市場は2023年に10億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに22億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは19.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.0％と12.9％と予測されています。欧州では、ドイツがCAGR 11.6%で成長すると予測されています。

世界の非アルコール性脂肪性肝疾患治療薬市場- 主要動向と促進要因のまとめ

非アルコール性脂肪性肝疾患（NAFLD）治療薬はヘルスケアにどのような影響を与えているか？

非アルコール性脂肪性肝疾患（NAFLD）の治療薬は、肥満や2型糖尿病に伴う有病率の上昇により、ヘルスケアにおいてますます重要性を増しています。NAFLDは、より重篤な非アルコール性脂肪性肝炎（NASH）に進行する可能性があり、肝硬変、肝不全、肝がんなどの転帰をたどる可能性があるため、医療システムにとって大きな負担となっています。NAFLDの効果的な治療法は、肝臓の炎症を抑え、脂肪の蓄積を防ぎ、線維化の進行を食い止めることです。現在、NAFLDの管理は食事療法や運動療法などの生活習慣の改善によるところが大きいが、新たな薬物療法は特定の代謝経路に着目し、NAFLDをより効果的に治療・管理するものです。こうした治療法の進歩は、肝移植の必要性を減らし、進行性肝疾患に伴う罹患率や死亡率を低下させる可能性があります。

NAFLD治療薬の機能性を高める技術革新とは？

NAFLD治療薬の革新には、肝代謝、炎症、線維化に関与する複数の経路を標的とする薬剤の開発が含まれます。脂肪代謝や炎症を制御する肝特異的酵素や受容体などの分子標的を対象とした研究がますます盛んになっています。例えば、PPARアゴニスト、SGLT2阻害剤、FXRアゴニストを含む新しいクラスの薬剤は、肝機能を改善し、肝脂肪を減少させ、線維化を予防する可能性が検討されています。さらに、非侵襲的画像診断やバイオマーカーなどの診断技術の進歩により、これらの治療法の有効性を正確に評価する能力が向上し、より個別化された治療アプローチが可能になりつつあります。これらの技術革新は、NAFLD患者の予後を改善することを約束するだけでなく、現在の選択肢に比べて投与が容易で副作用の少ない治療を提供することを目指しています。

NAFLD治療薬は患者の転帰とヘルスケアコストにどのような影響を与えるか？

NAFLDに対する効果的な治療薬は、疾患の進行を遅らせ、肝臓関連の合併症の発生率を低下させ、肝臓全体の健康を改善することにより、患者の転帰を著しく改善する可能性があります。NAFLDからNASHや肝硬変のようなより重篤な病期への進行を予防することで、これらの治療は、管理や治療に費用のかかる肝不全や肝がんの可能性を減少させることができます。早期かつ効果的な介入により、入院や肝移植の必要性、その他の高額なヘルスケア介入を減らすことができます。その結果、NAFLDの効果的な治療法が開発・採用されれば、ヘルスケアの大幅な節約につながり、慢性肝疾患に関連する経済的負担の全体的な軽減に貢献することができます。

NAFLD治療薬市場の成長を牽引する動向とは？

NAFLD治療薬市場の成長は、肥満と糖尿病の世界の罹患率の増加、NAFLDが深刻な健康状態であるという認識の高まり、効果的な薬理学的治療に対するアンメットニーズなど、いくつかの動向によって牽引されています。肥満とそれに関連する代謝疾患が世界的に蔓延するにつれ、NAFLDの発症率は上昇を続け、治療的介入に対する需要が高まっています。さらに、医療界や一般市民の間でNAFLDとNASHの認知度が高まるにつれ、スクリーニングの普及と早期診断が促され、治療ソリューションに対する需要がさらに高まっています。現在の治療選択肢は限られているため、新規治療薬の開発に対する継続的な研究と投資も重要です。治療を必要とする患者数が増加の一途をたどっていることから、効果的な新薬のイントロダクションが実現すれば、市場は急速に拡大する可能性があります。これらの動向は、NAFLD治療薬市場のダイナミックな性質を浮き彫りにし、この分野における継続的な革新と開発の必要性を強調しています。

調査対象企業の例（注目の48社）

  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Belite Bio Inc.
  • Boehringer Ingelheim International GmbH
  • Cardax, Inc.
  • Elixir Rx Solutions, LLC
  • Lin BioScience, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Peptron, Inc.
  • Pfizer, Inc.
  • Poxel SA.
  • Theratechnologies
  • Viking Therapeutics;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24265

Global Non-Alcoholic Fatty Liver Disease Therapeutics Market to Reach US$9.7 Billion by 2030

The global market for Non-Alcoholic Fatty Liver Disease Therapeutics estimated at US$3.7 Billion in the year 2023, is expected to reach US$9.7 Billion by 2030, growing at a CAGR of 14.6% over the analysis period 2023-2030. Oral Route, one of the segments analyzed in the report, is expected to record a 15.0% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Parenteral Route segment is estimated at 13.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 19.5% CAGR

The Non-Alcoholic Fatty Liver Disease Therapeutics market in the U.S. is estimated at US$1.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 19.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.0% and 12.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Global Non-Alcoholic Fatty Liver Disease Therapeutics Market - Key Trends and Drivers Summarized

How Are Therapeutics for Non-Alcoholic Fatty Liver Disease (NAFLD) Impacting Healthcare?

Therapeutics for Non-Alcoholic Fatty Liver Disease (NAFLD) are becoming increasingly crucial in healthcare due to the rising prevalence of the disease associated with obesity and type 2 diabetes. NAFLD, which can progress to more severe non-alcoholic steatohepatitis (NASH), represents a significant burden on health systems, with potential outcomes including cirrhosis, liver failure, and liver cancer. Effective therapeutics for NAFLD aim to reduce liver inflammation, prevent the accumulation of fat, and halt the progression of fibrosis. Currently, management of NAFLD largely depends on lifestyle changes like diet and exercise; however, emerging drug therapies are focusing on specific metabolic pathways to better treat and manage the condition. These advancements in treatment options can potentially reduce the need for liver transplantation and decrease the morbidity and mortality associated with advanced liver disease.

What Innovations Are Enhancing the Functionality of NAFLD Therapeutics?

Innovations in NAFLD therapeutics include the development of drugs that target multiple pathways involved in liver metabolism, inflammation, and fibrosis. Research is increasingly focusing on molecular targets such as liver-specific enzymes and receptors that regulate fat metabolism and inflammation. For instance, new classes of drugs, including PPAR agonists, SGLT2 inhibitors, and FXR agonists, are being explored for their potential to improve liver function, reduce liver fat, and prevent fibrosis. Additionally, advancements in diagnostic technologies, such as non-invasive imaging and biomarkers, are enhancing the ability to accurately assess the efficacy of these therapies, enabling more personalized treatment approaches. These innovations not only promise to improve outcomes for patients with NAFLD but also aim to provide treatments that are easier to administer and have fewer side effects compared to current options.

How Do NAFLD Therapeutics Impact Patient Outcomes and Healthcare Costs?

Effective therapeutics for NAFLD have the potential to significantly improve patient outcomes by slowing disease progression, reducing the incidence of liver-related complications, and improving overall liver health. By preventing the progression from NAFLD to more severe stages like NASH or cirrhosis, these treatments can decrease the likelihood of liver failure and liver cancer, which are costly to manage and treat. Early and effective intervention can reduce hospitalizations, the need for liver transplantation, and other expensive healthcare interventions. Consequently, the development and adoption of effective NAFLD treatments can lead to substantial healthcare savings and contribute to the overall reduction in the economic burden associated with chronic liver diseases.

What Trends Are Driving Growth in the NAFLD Therapeutics Market?

The growth of the NAFLD therapeutics market is driven by several trends, including the increasing global incidence of obesity and diabetes, greater awareness of NAFLD as a serious health condition, and the unmet need for effective pharmacological treatments. As obesity and related metabolic conditions become more prevalent worldwide, the incidence of NAFLD continues to rise, creating a growing demand for therapeutic interventions. Additionally, increased recognition of NAFLD and NASH in the medical community and among the public is prompting more widespread screening and earlier diagnosis, which further fuels the demand for treatment solutions. Ongoing research and investment in the development of novel therapeutics are also significant, as current treatment options are limited. The potential introduction of new and effective drugs could rapidly expand the market, given the large and growing number of patients in need of treatment. These trends highlight the dynamic nature of the NAFLD therapeutics market and underscore the critical need for continued innovation and development in this area.

Select Competitors (Total 48 Featured) -

  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Belite Bio Inc.
  • Boehringer Ingelheim International GmbH
  • Cardax, Inc.
  • Elixir Rx Solutions, LLC
  • Lin BioScience, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Peptron, Inc.
  • Pfizer, Inc.
  • Poxel SA.
  • Theratechnologies
  • Viking Therapeutics;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Non-Alcoholic Fatty Liver Disease Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Obesity and Diabetes Catalyzes Demand for NAFLD Treatments
    • Increasing Public Awareness and Screening for Early Detection of Fatty Liver Disease
    • Emergence of Combination Therapies to Enhance Treatment Efficacy
    • Developments in Biomarkers for Non-Invasive Diagnosis and Monitoring
    • Insurance Coverage and Reimbursement Scenarios Affecting Patient Care
    • Technological Advancements in Liver Imaging Techniques
    • Rising Demand for Herbal and Natural Products for Liver Health
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-Alcoholic Fatty Liver Disease Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • JAPAN
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • CHINA
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • EUROPE
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • FRANCE
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • GERMANY
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • INDIA
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030
  • AFRICA
    • Non-Alcoholic Fatty Liver Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Non-Alcoholic Fatty Liver Disease Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2014, 2024 & 2030

IV. COMPETITION